LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Viridian Therapeutics today and set a price target of $46.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight the potential of Viridian Therapeutics in the treatment of Thyroid Eye Disease (TED). The recent disappointing results from Roche’s satralizumab studies have reinforced the position of IGF-1R inhibitors as the leading therapeutic option in this space, with VRDN-003 emerging as a promising subcutaneous therapy.
The completion of enrollment in Viridian’s REVEAL program, which is evaluating VRDN-003, positions the company well for future success. The anticipated positive topline data in 2026 could pave the way for a Biologics License Application submission by the end of that year. Additionally, the potential preference for a low-volume, self-administered autoinjector among patients further supports the competitive edge of VRDN-003 in the market.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $40.00 price target.